Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nomura Establishes Japanese Generics And Biotech Investment Funds

This article was originally published in PharmAsia News

Executive Summary

Japanese investment bank Nomura announced June 18 that it would establish investment funds containing a basket of generic drug makers and biotech companies June 24. Nomura Asset Management hopes to capitalize on current and future growth in the sectors. Japanese generic makers' share prices jumped on the news. Towa Pharmaceutical led the pack with ¥220 up for the day, marking a new high for the year. Saiwai Pharmaceutical's share price also increased by ¥170 to ¥5,270, also a new high for Japan's largest generic maker. Nichi-Iko shares rose for four days in a row. Another maker Fuji Pharmaceutical, however, saw shares drop by ¥18 due to heavy dependence on a single distributor. Since a diagnostic procedure combined payment system is expanding among hospitals in Japan, the generic drug market is expected to grow further. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel